PTGX (Protagonist Therapeutics) Forward P/E Multiple
What are the growth horizons for Protagonist Therapeutics (PTGX) given its peptide platform patents and royalties from industry behemoths? The answer is provided by the company's forward P/E, where 0.00 determines the latest valuation metric. This price action reflects the dependence of drug production on the reliability of external contract manufacturing organizations (CMO). Ultimately, business stability is ensured by US R&D centers and innovations in hematology treatment.
Analytical breakdowns for Protagonist Therapeutics
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Protagonist Therapeutics|PTGX - Long-Term Debt to Capital|Short-Term Debt to Equity Protagonist Therapeutics Inc|PTGX - Company Aggregate Debt|Debts to Book Capitalization Protagonist Therapeutics, Inc.|PTGX - Long-Term Debt|Company Short-Term Debt Protagonist Therapeutics|Quick Liquidity protagonist-inc.com
- company profitability and valuation multiples indicators:
PTGX - Final Profit|Expected Profit Protagonist Therapeutics|PTGX - Market Cap to Earnings|Projected Price to Earnings Protagonist Therapeutics Inc|PTGX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Protagonist Therapeutics Inc|PTGX - Operating profit EBITDA|Net earnings per share (EPS TTM) Protagonist Therapeutics|PTGX - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months protagonist-inc.com|PTGX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Protagonist Therapeutics
- total revenue and sales volume data:
Summary company analytics:protagonist-inc.com
The forward P/E compares the current market value of Protagonist Therapeutics (PTGX) with expected net income, allowing for an assessment of the cost of one dollar of future earnings while filtering out short-term market noise. For a non-cyclical biopharmaceutical business dependent on clinical trial results, the company's forward price-to-earnings ratio becomes a key indicator of fundamental value, independent of macroeconomic recessions.
Competitors of Protagonist Therapeutics (PTGX)
Projected Price to Earnings ARGX (Argenx)|BNTX (BioNTech Group) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (Abivax SA)|Market Cap to Projected Earnings admabiologics.com (ADMA)|IMVT - Future Price to Earnings|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Projected Price to Earnings|Grifols Biemat (GRFS) - Future Price to Earnings|Projected Price to Earnings Adaptive Biotechnologies|Projected Price to Earnings CLDX|Forward P/E Multiple auriniapharma.com|Future Price to Earnings BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Future Earnings Ratio|Forward P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Projected Price to Earnings Ratio|AbCellera Biologics - Forward P/E Multiple|tourmalinebio.com - Market Cap to Future Earnings Ratio|Precigen (PGEN) - Future Price to Earnings|Pharming Group - Future Price to Earnings Multiple|Future Price to Earnings Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ZBIO|Forward P/E Multiple immunome.com (IMNM)|Forward P/E Multiple GOSS (gossamerbio.com)|Market Cap to Projected Earnings KalVista Pharma (KALV)|SEPN - Future Price to Earnings|Market Cap to Projected Earnings Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Projected Price to Earnings|Price to Expected Earnings Ratio RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - Forward P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Future Price to Earnings engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Future Price to Earnings Multiple|Aerovate Therapeutics - Projected Price to Earnings|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics, Inc - Forward P/E Multiple|Price to Expected Earnings Ratio TLSA|CABA: Forward P/E Multiple|Projected Price to Earnings Ventyx Bio|Future Price to Earnings Theratechnologies, Inc.|Projected Price to Earnings Ratio Avalo Therapeutics AVTX|Forward P/E Multiple ELDN|AGEN (Agenus, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|adagene.com (ADAG) - Projected Price to Earnings|Ikena Oncology (IMA) - Future Price to Earnings|Projected Price to Earnings Shattuck Labs, Inc.|Future Price to Earnings equilliumbio.com|Projected Price to Earnings connectbiopharm.com (CNTB)|Forward P/E Multiple IMUX|Market Cap to Projected Earnings Atara Bio|Future Price to Earnings InflaRx N.V. IFRX|X4 Pharmaceuticals - Future Price to Earnings|ACET: Projected Price to Earnings|Future Price to Earnings Multiple CELU (celularity.com)|INMB: Forward P/E Multiple|BRNS: Market Cap to Future Earnings Ratio|KZR (Kezar Life Sciences, Inc.) - Forward P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Market Cap to Projected Earnings|Forward P/E Multiple AKTX|Future Price to Earnings ENLV (Enlivex Therapeutics Ltd)|Future Price to Earnings Q32 Bio Inc. QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|Projected Price to Earnings Ratio iBio|CARM: Forward P/E Multiple|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals, Ltd.)|Future Price to Earnings boltbio.com|Forward P/E Multiple HCW Biologics|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt Inc.)|Market Cap to Projected Earnings GRI Bio, Inc. (GRI)|XRTX - Future Price to Earnings|reshapelifesciences.com (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple
